{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:13:25Z","timestamp":1794572005396,"version":"4.9.1"},"reference-count":12,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"10","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2022.281214","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T03:59:38Z","timestamp":1656561578000},"page":"2501-2505","source":"Crossref","is-referenced-by-count":54,"title":["Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-na\u00efve acute myeloid leukemia"],"prefix":"10.3324","volume":"107","author":[{"given":"Naseema","family":"Gangat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isla","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiqa","family":"Farrukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref","family":"Al-Kali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Alkhateeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kebede","family":"Begna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Mangaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mithun","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayalew","family":"Tefferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"40725","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"40726","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Tiong IS, Quaglieri A. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood. 2020; 135(11):791-803.","DOI":"10.1182\/blood.2019003988"},{"key":"40727","doi-asserted-by":"crossref","unstructured":"Pollyea DA, DiNardo CD, Arellano ML. Impact of venetoclax and azacitidine in treatment-naive patients with acute myeloid leukemia and IDH1\/2 mutations. Clin Cancer Res. 2022; 28(13):2753-2761.","DOI":"10.1158\/1078-0432.CCR-21-3467"},{"key":"40728","doi-asserted-by":"crossref","unstructured":"Agarwal SK, DiNardo CD, Potluri J. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017; 39(2):359-367.","DOI":"10.1016\/j.clinthera.2017.01.003"},{"key":"40729","doi-asserted-by":"crossref","unstructured":"Dohner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"40730","doi-asserted-by":"crossref","unstructured":"Devillier R, Mansat-De Mas V, Gelsi-Boyer V. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget. 2015; 6(10):8388-8396.","DOI":"10.18632\/oncotarget.3460"},{"key":"40731","doi-asserted-by":"crossref","unstructured":"Pratz KW, Jonas BA, Pullarkat V. Measurable residual disease response and prognosis in treatment-naive acute myeloid leukemia with venetoclax and azacitidine. J Clin Oncol. 2022; 40(8):855-865.","DOI":"10.1200\/JCO.21.01546"},{"key":"40732","doi-asserted-by":"crossref","unstructured":"Bogenberger JM, Kornblau SM, Pierceall WE. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014; 28(8):1657-1665.","DOI":"10.1038\/leu.2014.44"},{"key":"40733","doi-asserted-by":"crossref","unstructured":"Rahmani NE, Ramachandra N, Sahu S. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine. Blood Cancer J. 2021; 11(9):157.","DOI":"10.1038\/s41408-021-00541-0"},{"key":"40734","doi-asserted-by":"crossref","unstructured":"Aldoss I, Yang D, Pillai R. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia. Am J Hematol. 2019; 94(10):E253-E255.","DOI":"10.1002\/ajh.25567"},{"key":"40735","doi-asserted-by":"crossref","unstructured":"Ball BJ, Famulare CA, Stein EM. Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Adv. 2020; 4(13):2866-2870.","DOI":"10.1182\/bloodadvances.2020001482"},{"key":"40736","doi-asserted-by":"crossref","unstructured":"Garciaz S, Hospital MA, Alary AS. Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients. Cancers (Basel). 2022; 14(8):2025.","DOI":"10.3390\/cancers14082025"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281214\/74620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281214\/74906","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10700\/74620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:01:55Z","timestamp":1794045715000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":12,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281214","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}